Baxter pumps E75m into Ireland:
This article was originally published in Clinica
Baxter International has unveiled plans to invest E75m ($110m) over a six-year period to enhance its existing operations in Ireland. With the support of the country's industrial development agency (IDA Ireland), the company will use the money to introduce new medical manufacturing technologies, upgrade its facilities and provide extensive re-training of its existing workforce. Baxter has two manufacturing facilities in the country: the Castlebar plant produces continuous ambulatory peritoneal dialysis systems and intravenous medical solutions, while the Swinford facility manufactures a range of medical accessories for renal therapy. The firm, which has over 1,000 employees in Ireland, also has a sales and marketing operation based in Dublin.
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.